Should I buy or sell GeoVax Labs stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GeoVax Labs in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GOVX shares. View GOVX analyst ratings or view top-rated stocks .

What is GeoVax Labs' stock price target for 2024?

2 brokers have issued 1 year target prices for GeoVax Labs' shares. Their GOVX share price targets range from $4.00 to $8.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,300.2% from the stock's current price. View analysts price targets for GOVX or view top-rated stocks among Wall Street analysts .

How have GOVX shares performed in 2023?

GeoVax Labs' stock was trading at $0.6302 at the beginning of 2023. Since then, GOVX shares have decreased by 32.0% and is now trading at $0.4285. View the best growth stocks for 2023 here .

Are investors shorting GeoVax Labs?

GeoVax Labs saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 634,200 shares, a decrease of 24.2% from the October 31st total of 836,900 shares. Based on an average trading volume of 214,700 shares, the days-to-cover ratio is currently 3.0 days. View GeoVax Labs' Short Interest .

When is GeoVax Labs' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our GOVX earnings forecast .

How were GeoVax Labs' earnings last quarter?

GeoVax Labs, Inc. (NASDAQ:GOVX) posted its earnings results on Wednesday, November, 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.15.

How do I buy shares of GeoVax Labs?

Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

GeoVax Labs Stock Price, News & Analysis (NASDAQ:GOVX)

$0.43

0.00 (0.00%)

(As of 11/30/2023 ET)

Compare

Today's Range: $0.41
▼
$0.44
50-Day Range: $0.43
▼
$0.59
52-Week Range: $0.41
▼
$1.39

Volume: 187,936 shs
Average Volume: 722,290 shs
Market Capitalization: $11.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

GeoVax Labs MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,300.2% Upside
$6.00 Price Target
Short Interest: Healthy
2.38% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.77
Based on 6 Articles This Week
Insider Trading: Acquiring Shares
$5,020 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.73) to ($0.62) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

272nd out of 949 stocks

Pharmaceutical Preparations Industry

107th out of 433 stocks

3.5

Analyst's Opinion

Consensus Rating
GeoVax Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, GeoVax Labs has a forecasted upside of 1,300.2% from its current price of $0.43.
Amount of Analyst Coverage
GeoVax Labs has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.38% of the outstanding shares of GeoVax Labs have been sold short.
Short Interest Ratio / Days to Cover
GeoVax Labs has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in GeoVax Labs has recently decreased by 24.22%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
GeoVax Labs does not currently pay a dividend.
Dividend Growth
GeoVax Labs does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GOVX.

2.1

News and Social Media Coverage

News Sentiment
GeoVax Labs has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for GeoVax Labs this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GeoVax Labs insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,020.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.00% of the stock of GeoVax Labs is held by insiders.
Percentage Held by Institutions
Only 6.09% of the stock of GeoVax Labs is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for GeoVax Labs are expected to grow in the coming year, from ($0.73) to ($0.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GeoVax Labs is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GeoVax Labs is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GeoVax Labs has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About GeoVax Labs Stock (NASDAQ:GOVX)

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

GOVX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GOVX Stock News Headlines

November 30, 2023 | finance.yahoo.com

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

November 29, 2023 | finance.yahoo.com

GeoVax to Participate in Upcoming December Investor Events

December 1, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 28, 2023 | finance.yahoo.com

GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress

November 27, 2023 | msn.com

Geovax Labs (GOVX) Price Target Increased by 12.50% to 6.12

November 10, 2023 | finance.yahoo.com

GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2023 Earnings Call Transcript

November 9, 2023 | finanznachrichten.de

GeoVax, Inc.: GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

November 7, 2023 | benzinga.com

Geovax Labs Earnings Preview

December 1, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

October 31, 2023 | finance.yahoo.com

GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023

October 24, 2023 | finance.yahoo.com

GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

October 5, 2023 | finanznachrichten.de

GeoVax, Inc.: GeoVax Receives Notice of Allowance for HIV Vaccine Patent

September 27, 2023 | finance.yahoo.com

GeoVax to Participate in Upcoming October Investor and Industry Events

September 26, 2023 | markets.businessinsider.com

GeoVax Labs Secures License Agreement With ProBioGen

September 19, 2023 | finance.yahoo.com

GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

September 12, 2023 | finance.yahoo.com

GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference

September 11, 2023 | finance.yahoo.com

GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

August 31, 2023 | msn.com

Geovax Labs (GOVX) Price Target Increased by 11.11% to 6.12

August 31, 2023 | finance.yahoo.com

GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 28, 2023 | finanznachrichten.de

GeoVax, Inc.: GeoVax Receives Notice of Allowance for Malaria Vaccine Patent

August 11, 2023 | finance.yahoo.com

GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2023 Earnings Call Transcript

July 26, 2023 | finance.yahoo.com

GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023

July 24, 2023 | markets.businessinsider.com

GeoVax Labs (GOVX) Gets a Buy from Noble Financial

July 24, 2023 | finance.yahoo.com

GeoVax Announces Issuance of Ebola Vaccine Patent

July 20, 2023 | finanznachrichten.de

GeoVax, Inc.: GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

July 20, 2023 | finance.yahoo.com

GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

June 28, 2023 | finance.yahoo.com

GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference

See More Headlines

Receive GOVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 11/30/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GOVX
CUSIP: N/A
CIK: 832489
Web: www.geovax.com
Phone: (678) 384-7220
Fax: 678-384-7281
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.00
High Stock Price Target: $8.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +1,300.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,020,000.00
Net Margins: N/A
Pretax Margin: -2,375,800.00%
Return on Equity: -126.41%
Return on Assets: -99.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.09
Quick Ratio: 2.09

Sales & Book Value

Annual Sales: $80,000.00
Price / Sales: 142.96
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.34 per share
Price / Book: 1.26

Miscellaneous

Outstanding Shares: 26,690,000
Free Float: 25,627,000
Market Cap: $11.44 million
Optionable: Not Optionable
Beta: 2.93

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. David Alan Dodd (Age 73)
Chairman, President & CEO
Comp: $469.01k
Mr. Mark W. Reynolds CPA (Age 61)
CFO & Corporate Secretary
Comp: $348.2k
Dr. Mark J. Newman Ph.D. (Age 68)
Chief Scientific Officer
Comp: $364.17k
Dr. Harriet Latham Robinson Ph.D. (Age 85)
Founder & Member of Scientific Advisory Board
Dr. Kelly T. McKee Jr. (Age 73)
M.D., M.P.H., Chief Medical Officer
Jeffrey Welch
Head of Process Development & Manufacturing Operations
Dr. John W. Sharkey Ph.D. (Age 67)
Vice President of Business Development

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

GOVX Stock Analysis - Frequently Asked Questions

Should I buy or sell GeoVax Labs stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GeoVax Labs in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GOVX shares.
View GOVX analyst ratings or view top-rated stocks.
What is GeoVax Labs' stock price target for 2024?: 2 brokers have issued 1 year target prices for GeoVax Labs' shares. Their GOVX share price targets range from $4.00 to $8.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,300.2% from the stock's current price.
View analysts price targets for GOVX or view top-rated stocks among Wall Street analysts.
How have GOVX shares performed in 2023?: GeoVax Labs' stock was trading at $0.6302 at the beginning of 2023. Since then, GOVX shares have decreased by 32.0% and is now trading at $0.4285.
View the best growth stocks for 2023 here.
Are investors shorting GeoVax Labs?: GeoVax Labs saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 634,200 shares, a decrease of 24.2% from the October 31st total of 836,900 shares. Based on an average trading volume of 214,700 shares, the days-to-cover ratio is currently 3.0 days.
View GeoVax Labs' Short Interest.

When is GeoVax Labs' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our GOVX earnings forecast.
How were GeoVax Labs' earnings last quarter?: GeoVax Labs, Inc. (NASDAQ:GOVX) posted its earnings results on Wednesday, November, 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.15.
How do I buy shares of GeoVax Labs?: Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GOVX) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial